Alteration of beta-2-microglobulin level in malignant lymphoproliferative diseases after a high dose of alpha-2-recombinant interferon

• Published in: European journal of cancer & clinical oncology Vol. 24; no. 8; pp. 1295 - 1298
• Main Authors: Opat, Pavel, Drbal, Josef, Tauer, Zdeněk, Wotke, Richard
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.08.1988; New York, NY Pergamon Press
• Subjects: Adult; Antineoplastic agents; beta 2-Microglobulin - analysis; beta 2-Microglobulin - urine; Biological and medical sciences; Chemotherapy; Female; Humans; Interferon-gamma - therapeutic use; Lymphoma - blood; Lymphoma - drug therapy; Lymphoma - metabolism; Male; Medical sciences; Pharmacology. Drug treatments; Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism; Recombinant Proteins; Antineoplastic agent; Therapeutic efficiency; Human; Myeloproliferative syndrome; Intravenous administration; Alpha interferon; Perfusion; Immunotherapy; Serum; Tumoral marker; High dose; β2-Microglobulin
• ISSN: 0277-5379
• DOI: 10.1016/0277-5379(88)90218-0

A group of 10 patients with malignant lymphoproliferative diseases resistant to any standard therapeutical modalities were treated with a high dose of alpha- 2-recombinant interferon (alpha- 2-rIF). Alpha- 2-rIF was administered at a total dose of 120 × 10 6 IU in a continuous infusion during 48 h. Two cycles of alpha- 2-rIF immunotherapy were employed with an interval of 1 month in between each. Serum and urinary beta- 2-microglobulin (B 2M) were examined prior to alpha- 2-rIF application and on days 2, 4, 6 afterwards. Alpha- 2-rIF treatment induced an increase in serum B 2M as noted on day 2 followed by a decline to below the normal range. The initial increased value was significantly higher as compared to either the pretreatment value or the normal physiological range. The reduced B 2M serum level was protracted and lasted until the second cycle of treatment. Similar but not so great changes in B 2M serum values were noted during the second application of alpha- 2-rIF. The changes of B 2M level in the urine, although less convincing, mimic those observed in the serum. The present results confirmed the biological activity of alpha- 2-rIF in malignant lymphoproliferative diseases.